Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark
Product: Ryzodeginsulin degludec/insulin aspart (DegludecPlus, IDegAsp) (NN5401); Tresiba insulin degludec (NN1250)